Celldex Net Debt from 2010 to 2026

CLDX Stock

USD 23.76 1.18 5.23%

Celldex Therapeutics Net Debt yearly trend continues to be fairly stable with very little volatility. Net Debt will likely drop to about -23.2 M in 2026. Net Debt is the total debt of Celldex Therapeutics minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

1986-03-31

Previous Quarter

-20 M

Current Value

-33.4 M

Quarterly Volatility

23.7 M

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Check Celldex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Celldex Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.4 M, Interest Expense of 5.8 M or Selling General Administrative of 42.1 M, as well as many indicators such as Price To Sales Ratio of 219, Dividend Yield of 0.0 or PTB Ratio of 2.38. Celldex financial statements analysis is a perfect complement when working with Celldex Therapeutics Valuation or Volatility modules.

Build AI portfolio with Celldex Stock

Check out the analysis of Celldex Therapeutics Correlation against competitors.

For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.

The evolution of Net Debt for Celldex Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Celldex Therapeutics compares to historical norms and industry peers.

Latest Celldex Therapeutics' Net Debt Growth Pattern

Below is the plot of the Net Debt of Celldex Therapeutics over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Celldex Therapeutics' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Celldex Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Net Debt

Timeline

Celldex Net Debt Regression Statistics

	Arithmetic Mean	(34,265,049)
	Geometric Mean	22,615,292
	Coefficient Of Variation	(112.57)
	Mean Deviation	21,727,501
	Median	(25,396,000)
	Standard Deviation	38,570,477
	Sample Variance	1487.7T
	Range	172.9M
	R-Value	0.13
	Mean Square Error	1560.7T
	R-Squared	0.02
	Significance	0.62
	Slope	979,868
	Total Sum of Squares	23802.9T

Celldex Net Debt History

	2026	-23.2 M
	2025	-22.1 M
	2024	-24.5 M
	2023	-32.3 M
	2022	-25.4 M
	2021	-36.1 M
	2020	-40.4 M

Other Fundumenentals of Celldex Therapeutics

Net Debt To E B I T D A

Celldex Therapeutics Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Net Receivables	Accounts Payable	Short Term Debt	Common Stock	Intangible Assets	Current Deferred Revenue	Property Plant Equipment	Short Term Investments	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		1.0	-0.09	-0.73	0.2	0.99	0.03	0.83	-0.33	0.13	-0.02	0.27	0.13	0.97	0.8	-0.47	0.63	0.5	0.94	-0.73	0.94	0.78
Total Stockholder Equity	1.0		-0.09	-0.73	0.12	1.0	0.01	0.84	-0.38	0.07	-0.1	0.25	0.07	0.98	0.82	-0.45	0.64	0.46	0.95	-0.73	0.96	0.8
Net Debt	-0.09	-0.09		-0.13	-0.08	-0.08	0.02	-0.1	0.1	-0.39	0.05	-0.54	-0.43	0.05	-0.18	0.33	0.01	0.12	0.1	-0.11	0.13	0.14
Retained Earnings	-0.73	-0.73	-0.13		-0.12	-0.72	-0.39	-0.66	0.41	0.22	-0.17	0.01	0.11	-0.73	-0.71	0.61	-0.93	-0.71	-0.62	0.37	-0.71	-0.84
Total Liab	0.2	0.12	-0.08	-0.12		0.05	0.25	0.1	0.44	0.72	0.82	0.35	0.72	0.03	-0.1	-0.34	0.17	0.51	0.0	0.06	-0.04	-0.09
Total Current Assets	0.99	1.0	-0.08	-0.72	0.05		-0.01	0.84	-0.43	0.01	-0.18	0.24	0.03	0.99	0.84	-0.42	0.62	0.4	0.96	-0.73	0.96	0.82
Net Receivables	0.03	0.01	0.02	-0.39	0.25	-0.01		0.15	0.02	-0.05	0.4	-0.19	0.05	-0.01	-0.01	-0.28	0.36	0.45	-0.09	0.07	-0.03	0.11
Accounts Payable	0.83	0.84	-0.1	-0.66	0.1	0.84	0.15		-0.43	0.11	-0.12	0.31	0.15	0.82	0.72	-0.42	0.59	0.33	0.78	-0.58	0.78	0.71
Short Term Debt	-0.33	-0.38	0.1	0.41	0.44	-0.43	0.02	-0.43		0.34	0.51	0.14	0.43	-0.43	-0.58	0.1	-0.48	0.07	-0.39	0.11	-0.45	-0.64
Common Stock	0.13	0.07	-0.39	0.22	0.72	0.01	-0.05	0.11	0.34		0.37	0.67	0.79	-0.04	-0.03	-0.2	-0.13	0.21	-0.02	0.09	-0.12	-0.25
Intangible Assets	-0.02	-0.1	0.05	-0.17	0.82	-0.18	0.4	-0.12	0.51	0.37		-0.07	0.38	-0.18	-0.33	-0.32	0.18	0.6	-0.22	0.1	-0.21	-0.22
Current Deferred Revenue	0.27	0.25	-0.54	0.01	0.35	0.24	-0.19	0.31	0.14	0.67	-0.07		0.8	0.15	0.39	-0.38	0.06	0.0	0.1	0.05	0.03	0.0
Property Plant Equipment	0.13	0.07	-0.43	0.11	0.72	0.03	0.05	0.15	0.43	0.79	0.38	0.8		-0.05	0.06	-0.29	-0.06	0.12	-0.08	0.12	-0.16	-0.23
Short Term Investments	0.97	0.98	0.05	-0.73	0.03	0.99	-0.01	0.82	-0.43	-0.04	-0.18	0.15	-0.05		0.82	-0.37	0.62	0.41	0.98	-0.74	0.99	0.84
Net Tangible Assets	0.8	0.82	-0.18	-0.71	-0.1	0.84	-0.01	0.72	-0.58	-0.03	-0.33	0.39	0.06	0.82		-0.48	0.72	0.34	0.74	-0.47	0.78	0.8
Long Term Debt Total	-0.47	-0.45	0.33	0.61	-0.34	-0.42	-0.28	-0.42	0.1	-0.2	-0.32	-0.38	-0.29	-0.37	-0.48		-0.65	-0.52	-0.22	0.14	-0.27	-0.35
Capital Surpluse	0.63	0.64	0.01	-0.93	0.17	0.62	0.36	0.59	-0.48	-0.13	0.18	0.06	-0.06	0.62	0.72	-0.65		0.7	0.5	-0.17	0.6	0.83
Short Long Term Debt	0.5	0.46	0.12	-0.71	0.51	0.4	0.45	0.33	0.07	0.21	0.6	0.0	0.12	0.41	0.34	-0.52	0.7		0.33	-0.29	0.38	0.41
Net Invested Capital	0.94	0.95	0.1	-0.62	0.0	0.96	-0.09	0.78	-0.39	-0.02	-0.22	0.1	-0.08	0.98	0.74	-0.22	0.5	0.33		-0.77	0.99	0.8
Long Term Investments	-0.73	-0.73	-0.11	0.37	0.06	-0.73	0.07	-0.58	0.11	0.09	0.1	0.05	0.12	-0.74	-0.47	0.14	-0.17	-0.29	-0.77		-0.75	-0.41
Net Working Capital	0.94	0.96	0.13	-0.71	-0.04	0.96	-0.03	0.78	-0.45	-0.12	-0.21	0.03	-0.16	0.99	0.78	-0.27	0.6	0.38	0.99	-0.75		0.86
Capital Stock	0.78	0.8	0.14	-0.84	-0.09	0.82	0.11	0.71	-0.64	-0.25	-0.22	0.0	-0.23	0.84	0.8	-0.35	0.83	0.41	0.8	-0.41	0.86

Click cells to compare fundamentals

About Celldex Therapeutics Financial Statements

Celldex Therapeutics investors use historical fundamental indicators, such as Celldex Therapeutics' Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Celldex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	-22.1 M	-23.2 M
Net Debt To EBITDA	0.15	0.14

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

FSLY	Fastly Class A
MOB	Mobilicom Limited American
CMG	Chipotle Mexican Grill

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Celldex Net Debt from 2010 to 2026

Latest Celldex Therapeutics' Net Debt Growth Pattern

Celldex Net Debt Regression Statistics

Celldex Net Debt History

Other Fundumenentals of Celldex Therapeutics

Celldex Therapeutics Net Debt component correlations

About Celldex Therapeutics Financial Statements

Also Currently Popular

Additional Tools for Celldex Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY